Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Study of Postoperative Adjuvant Therapy of Uracil-tegafur (UFT) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil (CMF) in Breast Cancer (NSAS-BC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 75~* Performance status 0 or 1 (ECOG)~* Hematopoietic WBC ≥ 4,000/mm\^3 Platelet ≥ 100,000/mm\^3~* Hepatic AST and ALT ≤ 2.5 times upper limit of normal(ULN) Total bilirubin ≤ ULN~* Renal Creatinine ≤ ULN~Exclusion Criteria:~* Prior anticancer treatment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): UFT (uracil, tegafur)
- 2 (Type: ACTIVE_COMPARATOR): CMF(cyclophosphamide, methotrexate, and fluorouracil)

Based on this trial design, predict the completion outcome and termination type (if applicable).